Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions - Seite 2

About IIBR:

The Israel Institute for Biological Research was established in 1952 as a governmental research institute, founded by a group of scientists from the IDF Science Corps and from academic organizations. IIBR is located in the small city of Nes Ziona. Over the years, the Institute has been engaged in R&D in the fields of biology, chemistry and environmental sciences in order to provide the State of Israel with scientific response to chemical and biological threats. Alongside this specialized activity, IIBR scientists contributed to the development of a vaccine for polio (1959); developed kits for the detection of explosive materials (1980); developed a brand name drug against Sjogren syndrome (1984) marketed all over the world and is one of four brand name drugs developed in Israel. In 1991, a governmental company, Life Sciences Research Israel (LSRI) was established alongside the Institute and serves as its business and marketing arm. Since 1992, a unique laboratory for the nationwide diagnosis of diseases caused by the bacteria Rickettsia, Ehrlichia and Leptospira was established in IIBR. Since 1995, the Institute has operated as a government-affiliated unit that researches all areas of defense against chemical and biological weapons, including the operation of national laboratories for detection and identification of such treats. For more information, please visit www.iibr.gov.il.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.